Nurix Therapeutics, Inc. NRIX Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Nurix Therapeutics, Inc. (NRIX) reported common stock, shares authorized (in shares) of $500M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Nurix Therapeutics, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $500M to $500M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s common stock, shares authorized (in shares)?
- Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $500M to $500M.